673 related articles for article (PubMed ID: 19143635)
1. A complex interplay between Akt, TSC2 and the two mTOR complexes.
Huang J; Manning BD
Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
[TBL] [Abstract][Full Text] [Related]
2. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Huang J; Dibble CC; Matsuzaki M; Manning BD
Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
[TBL] [Abstract][Full Text] [Related]
3. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
4. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
5. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
[TBL] [Abstract][Full Text] [Related]
6. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
7. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
8. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
9. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
[TBL] [Abstract][Full Text] [Related]
10. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Dalle Pezze P; Sonntag AG; Thien A; Prentzell MT; Gödel M; Fischer S; Neumann-Haefelin E; Huber TB; Baumeister R; Shanley DP; Thedieck K
Sci Signal; 2012 Mar; 5(217):ra25. PubMed ID: 22457331
[TBL] [Abstract][Full Text] [Related]
11. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor.
Chen CC; Jeon SM; Bhaskar PT; Nogueira V; Sundararajan D; Tonic I; Park Y; Hay N
Dev Cell; 2010 Apr; 18(4):592-604. PubMed ID: 20412774
[TBL] [Abstract][Full Text] [Related]
12. CBAP regulates the function of Akt-associated TSC protein complexes to modulate mTORC1 signaling.
Liao WT; Chiang YJ; Yang-Yen HF; Hsu LC; Chang ZF; Yen JJY
J Biol Chem; 2023 Dec; 299(12):105455. PubMed ID: 37949232
[TBL] [Abstract][Full Text] [Related]
13. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
14. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
15. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
[TBL] [Abstract][Full Text] [Related]
16. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.
Han EK; Leverson JD; McGonigal T; Shah OJ; Woods KW; Hunter T; Giranda VL; Luo Y
Oncogene; 2007 Aug; 26(38):5655-61. PubMed ID: 17334390
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
[TBL] [Abstract][Full Text] [Related]
18. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets.
Moore SF; Hunter RW; Hers I
J Thromb Haemost; 2014 May; 12(5):748-60. PubMed ID: 24612393
[TBL] [Abstract][Full Text] [Related]
20. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
Kang YJ; Lu MK; Guan KL
Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
